Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by Gorf79on Jul 13, 2022 7:16am
232 Views
Post# 34819973

New Valuation - EAA revenue added US Only

New Valuation - EAA revenue added US OnlyMM-AP,

Ok I have run another NPV using what I think is the correct number of EAA units per treatment, but only for those that ulimately receive PMX and also only for the US.

Using conservative penetration figures, and again factoring in the restrictions noted above I came to $64.66 per share on a 290 mil float.

You guys are the only ones that care so maybe spit ball me a number on the rest of NA, all up all in revenue wise, plus EAA for ROW.

It's hard to do I know.

And that includes ZERO - supplies, maintenance kits or residual service contracts for the PMX and Dialysis pumps themselves.

If I included those I'd be pushing $100.00 per share.

The bashers will mock this but I'm an MBA and I spent my early post grad years doing exactly this.

I'm a little rusty but as the boys from Tropic Thunder might say I haven't gone Full Retard just yet.

Pete


<< Previous
Bullboard Posts
Next >>